Biotech Startups

Cardiac Insight develops ECG-based cardiac diagnostic products, including software using international consensus criteria, to help clinicians detect and screen for cardiac conditions such as sudden cardiac death risk in athletes. The company serves physicians and clinical settings in the cardiology and sports cardiology space, and is a subsidiary of Dreamtech.

4 investors

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.

4 investors

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

4 investors

Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases. It focuses on immunology and applies an mRNA platform to broaden the use of cell therapy for patients.

4 investors

Cascador Health provides real-world data analytics and clinical research services to pharmaceutical companies and healthcare organizations, focusing on market access, clinical evidence generation, and therapy adoption in healthcare. The company specializes in respiratory medicine and offers market sizing, epidemiological studies, health economics assessments, outcome measurement, and patient/physician engagement services.

4 investors

CasInvent Pharma develops pharmaceutical solutions, currently raising Series A funding through a crowdfunding campaign.

4 investors

Cauldron is an Australian biotech company using precision fermentation to produce alternative proteins. The company has demonstrated process efficiencies in fermentation-derived protein production that can significantly reduce production costs.

4 investors

Cayuga Biotech is a clinical-stage biotechnology company developing therapeutics for hemorrhage and blood-clotting-related conditions, with a lead candidate CAY001. It focuses on the hemostasis and thrombosis space, drawing on materials chemistry and translational medicine.

4 investors

Cebiotex is a biotech company developing innovative pharmaceutical products using proprietary nanofiber-based drug delivery technology, with a focus on oncology and surgical applications. The company pursues a partnership and licensing model with pharmaceutical firms to scale and distribute therapies globally.

4 investors

Cedience provides a SaaS platform that uses natural language processing and machine learning to help drug development teams quickly find evidence-backed answers to regulatory questions by centralizing and integrating regulatory databases. The platform serves pharmaceutical and biotech companies navigating drug development and regulatory approval processes.

4 investors

4 investors

CellChorus develops a visual AI platform called TIMING that performs high-throughput dynamic analysis of single cells, measuring cell activation, killing, and movement over time for biopharmaceutical research. The company serves biopharmaceutical companies and therapy developers seeking to understand cellular function and phenotype.

4 investors

Celltrion is a biopharmaceutical company that researches, develops, manufactures, and markets biosimilars and novel biologic therapeutics across therapeutic areas including immunology, oncology, hematology, ophthalmology, and endocrinology. Its products include ZYMFENTRA (subcutaneous infliximab) for inflammatory bowel disease and a range of FDA-approved biosimilars.

4 investors

Celularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.

4 investors

Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development. The company operates in the biotechnology and pharmaceutical industry.

4 investors

4 investors

Activating the immune system to recognize and destroy tumor cells. (NASDAQ: CMPI) (Acquired by Regeneron)

4 investors

Chromologics is a Danish biotech company that uses a precision fermentation platform to produce natural food colours, marketed to food and beverage manufacturers as an alternative to synthetic colourants. Its lead product, Natu.Red®, is a heat- and pH-stable red colourant compatible with kosher, halal, and vegan diets.

4 investors

Citizen Health builds a platform that gives patients with rare and complex diseases access to personalized guidance and allows them to share their health data to advance research and treatment development. The company serves patients and families navigating rare conditions, operating in the digital health and rare disease research space.

4 investors

Cime Therapeutics is developing a chemistry-first drug discovery platform that combines automation, AI/ML, and synthetic chemistry to make molecules faster and more cost-effectively. The platform integrates the synthesis and screening stages to accelerate the Design-Make-Test-Analyze cycle in pharmaceutical discovery.

4 investors

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands. The company aims to expand RNAi therapeutics beyond liver targeting to additional cell and tissue types.

4 investors

Clear Gene develops diagnostic tests used in cancer care that indicate to doctors whether a tumor has been fully removed. The company operates in the oncology and women's health diagnostics space.

4 investors

Cleara Biotech develops compounds to eliminate senescent cells for treating late-stage cancer and chronic age-related diseases. The company translates academic research on cellular senescence into clinical therapeutics.

4 investors

Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, it works to rehabilitate, use, and monetize its retained intellectual property.

4 investors